

MyCal - D

Calcium Carbonate & Vitamin D₃

COMPOSITION:

MyCal-D Tablet : Each film coated tablet contains Calcium Carbonate BP 1250 mg equivalent to 500 mg elemental Calcium and Vitamin D₃ 200 IU as Cholecalciferol BP.

INDICATION:

Calcium is an essential element and plays vital role in the body. It helps body's framework stronger by building bones. Vitamin D₃ is needed for Calcium to be absorbed from the gut, and deficiency can lead to low Calcium levels and subsequent weakening of bones.

This is indicated for the following treatment:

1. Osteoporosis, Rickets, Osteomalacia, Tetany and secondary Hyperparathyroidism.
2. As supplement during pregnancy and lactation due to increased demand.
3. For prevention and treatment of Calcium and Vitamin D₃ deficiency.

DOSAGE & ADMINISTRATION :

Adults and children above 12 years of age:

2 tablets per day, preferably one tablet each morning and evening with a full glass of water.

Children: Not recommended for children under 12 years.

CONTRAINDICATION:

Absolute contraindications are hypercalcemia, primary hyperparathyroidism, kidney stone, severe renal failures, Calcium and Vitamin D₃ over dosage, hypersensitivity to any of the ingredients. Relative contraindications are Osteoporosis due to prolonged immobilization, renal stones, and hypercalciuria.

SIDE EFFECTS:

The use of Calcium supplements has rarely given rise to mild gastrointestinal disturbances, such as constipation, flatulence, nausea, gastric pain, and diarrhoea. Following administration of Vitamin D₃ supplements occasional skin rash has been reported. Hypercalciuria, and in rare cases, hypercalcaemia have been seen with long term treatment at high dosages.

PRECAUTIONS:

Patients with mild to moderate renal failure or mild hypercalciuria should be supervised carefully. In patients with a history of renal stones urinary Calcium excretion should be measured to exclude hypercalciuria. With long term treatment it is advisable to monitor serum and urinary Calcium levels and kidney function, and reduce or stop treatment temporarily, if urinary Calcium exceeds 7.5 mili mole / 24 hours.

DRUG INTERACTIONS:

The risk of hypercalcemia should be considered in patients taking thiazide diuretics. Concomitant treatment with phenytoin or barbiturate can decrease the effect of Vitamin D₃ because of metabolic activation. Concomitant use of glucocorticoids can decrease the effect of Vitamin D₃. Calcium salts may reduce the absorption of thyroxin, sodium fluoride, quinolone or tetracycline antibiotics or iron.

OVERDOSE:

The most serious consequence of acute or chronic overdose is hypercalcemia due to Vitamin D₃ toxicity. Symptoms include nausea, vomiting and constipation. Chronic overdoses can lead to vascular and organ calcification as a result of hypercalcemia. Treatment should consist of stopping all intakes of Calcium and Vitamin D₃ and rehydration.

USE IN PREGNANCY & LACTATION:

It can be safely used during pregnancy and lactation, as Calcium and Vitamin D₃ requirements are increased in these cases. However, you should only use this medicine after consulting your doctor.

STORAGE:

Store below 30°C Temperature in a dry place. Keep away from light. Keep out of the reach of children.

PACKING:

MyCal-D Tablet Box : Each box containing 50 tablets in blister strip.

MyCal-D Tablet Pot : Each HDPE pot containing 30 tablets.

Manufactured by:

Novatek Pharmaceuticals Ltd.

Gilarchala, 7 Kewa Mouza, Sreepur, Gazipur, Bangladesh.

NOVATEK